OTC Link · Healthcare · Biotechnology
BIO-PATH HOLDINGS INC
**Nasdaq delisting** effective February 2025 compounds RNAi nanoparticle developer's challenges. Oncology-focused platform faces existential liquidity crisis with minimal market cap.
AI-generated summary — powered by BigEarnings.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-20 | Q1 2026 | — | -0.03 | — | $0 | — | +0.00% | +11.78% | — |
| 2025-08-14 | Q2 2025 | -0.40 | -0.55 | -37.50% | $0 | ❌ Miss | +0.00% | -12.73% | -54.33% |
| 2025-03-27 |
| Q4 2024 |
| -0.37 |
| -0.07 |
| +81.08% |
| $0 |
| ✅ Beat |
| -8.71% |
| -5.88% |
| -17.65% |
| 2024-11-15 | Q3 2024 | -1.02 | -0.70 | +31.37% | $0 | ✅ Beat | -7.68% | +0.92% | -17.55% |
| 2024-08-14 | Q2 2024 | -1.54 | -1.16 | +24.68% | $0 | ✅ Beat | -1.32% | -0.66% | -32.45% |
| 2024-05-14 | Q1 2024 | -4.80 | -4.88 | -1.67% | $0 | ❌ Miss | -13.18% | -22.48% | -22.48% |
| 2024-03-08 | Q4 2023 | -5.40 | -4.23 | +21.67% | $0 | ✅ Beat | — | — | — |
| 2023-11-15 | Q3 2023 | -6.80 | -6.40 | +5.88% | $0 | ✅ Beat | +1.20% | -7.14% | -11.92% |
Showing last 8 quarters.